Objectives: Human prion diseases are heterogeneous but invariably fatal neurodegenerative disorders with no known effective therapy. PRION-1, the largest clinical trial in prion disease to date, showed no effect of the potential therapeutic quinacrine on survival. Although there are several limitations to the usefulness of survival as an outcome measure, there have been no comprehensive studies of alternatives.
Prion diseases are invariably fatal neurodegenerative disorders with no therapy that is known to alter the natural history in man. 1 They comprise an etiologically and clinically heterogeneous group, with genetic, acquired, or sporadic etiologies. 2 Despite promising developments in basic science and experimental therapeutics, several challenges are evident in the development of clinical trial methodology. First, prion diseases are rare, with the implication that recruitment criteria need to be broad in order to achieve acceptable trial size in a reasonable geographic area or time scale. Second, the clinical phenotype is highly variable within and between each etiologic class. Third, there are strong influences on UK family members to reject randomization in trials which include the possibility of allocation to placebo. 3, 4 As a result, carefully documented historical control data may be important alternatives or adjuncts to a randomized placebocontrolled trial.
Any trial is dependent upon the relevance of its outcome measurement instruments. Mortality has been the choice of primary outcome in several prion disease trials/studies, but this is problematic for several reasons. 1, 5, 6 The immediate cause of death in prion disease, usually sepsis or respiratory failure, can be influenced by several factors unrelated to underlying disease progression, such as use of antibiotics to treat lifethreatening infections, and supplementary nutrition. As the aim is to halt or reverse neuropsychiatric impairments with a therapeutic intervention, a more relevant trial outcome measure should consider human prion disease progression directly.
METHODS PRION-1 study design. was an open-label patient-preference trial in which patients were offered a choice between taking quinacrine, not taking quinacrine, or being randomized to immediate quinacrine or quinacrine deferred for 24 weeks (appendix e-1 on the Neurology ® Web site at www.neurology.org). The objective was to obtain data on the effect of quinacrine in human prion disease, from a randomized comparison where acceptable and otherwise from observational comparisons. Full details of randomization, primary outcome, and adverse events in the pilot and main trial phases have been published. 3 Patients were assessed at baseline (enrollment) with follow-up at 1, 2, 4, and 6 months and then 3-monthly including a standardized clinical examination, the Glasgow Coma Scale (GCS), 7 Mini-Mental State Examination (MMSE), 8 cognitive component of the Alzheimer's Disease Assessment Scale (ADAS-cog), 9 Brief Psychiatric Rating Scale (BPRS), 10 Clinical Dementia Rating Scale Sum of Boxes (CDR-SB), 11 Global Impression of Change (GIC), 12 Rankin scale, 13 and the Barthel Activities of Daily Living Index 14 (see appendix e-1). , death, or loss to follow-up were estimated using mixed models, allowing individual random effects for intercept (enrollment value) and slope (decline). For more detail, sensitivity analyses, and subgrouping, see appendix e-1.
Standard protocol approvals, registrations, and patient

RESULTS Recruitment and follow-up summary.
The headline results of PRION-1 have been published. 3 Here we describe the pertinent recruitment and survival data needed to understand the scales analysis. A total of 107 patients were recruited in the pilot and main phases of the PRION-1 trial. A total of 45 had sporadic Creutzfeldt-Jakob disease (sCJD), 43 inherited prion disease (IPD), and 19 acquired prion diseases (17/19 variant CJD) (note that one fewer patient had variant Creutzfeldt-Jakob disease [vCJD] than reported in 3 due to a late reclassification as IPD). Diagnosis was confirmed by tissue biopsy, at autopsy, or by detection of a genetic mutation in 78/107. Seventy-eight of 107 patients died during the PRION-1 trial (to March 30, 2007) . Including additional data from patients still alive and in follow-up on March 30, 2007, from the National Prion Monitoring Cohort to date, in total 29/107 (27%) died within 4 weeks of enrollment, 34 (32%) within 6 weeks, 45 (42%) within 16 weeks, and 75 (70%) within 2 years. See appendix e-2 for details of follow-up and data to support lack of efficacy of quinacrine.
Cross-sectional performance of scales at recruitment of symptomatic patients. Table 1 shows completion rates for the various scales at recruitment for the 101/107 (94%) patients with symptomatic prion disease at enrollment, overall and according to Rankin. Almost universal completion rates were seen for the global clinicianrated scales (Rankin, GIC) reflecting their simplicity. Very high completion rates were also obtained for the Barthel and GCS (taking into consideration that the Barthel was not used in the pilot phase 3 and, following the protocol, GCS was not formally recorded if the MMSE was Ն10 but was rather imputed as 15 in main analyses). The CDR-SB was reasonably well completed but required the participation of a carer who may not have been available at the time. Cognitive scales (MMSE, ADAS-cog) were completed in around half and one-third, respectively, either because of aphasia or advanced stage of disease. The BPRS was only completed in 28/76 participants recruited during the main phase because of the need for a lengthy patient interview. Figure 1A illustrates the distribution of observed scores at enrollment, categorizing scores as being at the maximum possible (ceiling, best performance), at the minimum possible (floor, worst performance), or within intermediate terciles (low scores are worst for all rating scales; see appendix e-1). Despite low completion rates, most of those able to complete the cognitive and psychiatric scales scored in the upper terciles. These effects were present to a lesser extent for CDR-SB: in contrast, although Rankin was nearly universally completed, almost 40% of participants already registered the lowest score (floor) at enrollment. Overall, therefore, proportions at this lowest level or unable to complete were similar for the Rankin and CDR-SB. The Barthel, GIC, and GCS had the smallest proportion of patients already registering the worst possible score at enrollment. The only scale to show any significant ceiling effect (i.e., several patients with the best possible score at enrollment) was the GCS.
Completeness of rating scale observations over time.
In order to compare interventions in terms of changes in neurologic rating scales, it is imperative that as many of the scheduled assessments as possible are made. This requires attendance at scheduled visits and completion of each test, which may become increasingly problematic as the battery increases in size. In PRION-1, 10%-20% of scheduled visits were not made in patients still known to be alive during the first 36 weeks, declining thereafter to about 5%.
Early in the trial most missed visits were due to patients with sporadic CJD becoming moribund. Unsurprisingly, completion of all scales was also strongly impacted by mortality ( figure 1B ). However, rating scales were not always completed in patients attending visits, for similar reasons as at enrollment. Table 1 shows that between 50% and 75% of the individuals enrolled had Table 1 Characteristics of participants and completion of neurologic rating scales at enrollment into PRION-1 and subsequently only 0 or 1 measurement for the CDR-SB and BPRS, whereas 60%-65% of all patients, and even 32%-35% of severely affected patients, had 2 or more measurements of Barthel and GCS.
Change in rating scales over time. Some general comments can be made about the patterns of decline recorded in PRION-1, although detailed analysis of factors affecting rates of decline are beyond the scope of this manuscript. Individual patient trajectories are shown for all scales ( figure 2) . First, as expected, rates of decline were highly heterogeneous. Second, patients tend to follow linear patterns of decline, at least until the most advanced stages of disease. At this point several patients appear to reach a preterminal plateau, although it is unclear whether this observation is related to the insensitivity of scales at the advanced stages of disease, or reflects a true disease phenomenon. In figure 2 (see parts D, E, F, I), this phenomenon is illustrated by connecting the time of death (red point) denoted at the worst possible score on each scale with the measured value at last visit (orange line). Finally, for a reasonable proportion of patients, the last observed measurement before death is relatively far above the worst possible score on the scale (see figure 2 , parts A, B, C, H)-this is a consequence of rapidity of decline in late-stage dis-ease not covered by the visit schedule, inability to complete the scales with more severe disease (hence absence of further measurements), and the fact that death from human prion disease is often not specifically related to underlying neuropsychiatric decline (e.g., through aspiration pneumonia).
Performance of models used to describe change in rating scales over time. We estimated annual rates of decline overall, and in fast (sCJD)/medium (vCJD and some IPD, see appendix e-1)/slow progressors (Gerstmann-Straussler-Scheinker), mild to moderate disease stratified by Rankin (2-3 or 2-4), using both observed data only (table 2) and including all symptomatic patients but censoring after the first observed worst possible score for each scale and imputing death as the worst possible score ( figure 3 ). In different disease categories we found no evidence of differences in psychiatric/cognitive scores (MMSE, ADAS-cog, BPRS) at enrollment (p Ͼ 0.1) although all functional and clinician-rated scales were worst in "fast" and best in "slow" progressors (p Ͻ 0.0001, table 2). However, we found evidence for significant variation in the annual rate of decline after enrollment both by severity and disease category for all scales (p Ͻ 0.01, table 2) except BPRS, which had problems with completion as noted above. As expected, the annual rate of decline was greater in "medium" compared to "slow" progressors. However, "fast" progressors (sCJD) had smaller estimated declines than "medium" progressors as a consequence of their very low scores at enrollment, meaning that further declines were limited and therefore estimates of rates of decline are unreliable. With this exception, these data support the behavior of the rating scales as expected, and emphasize the need to diagnose sCJD at earlier stages if such rating scales are to be used as outcome measures in this population. Imputing death as the worst possible score increased the rate of decline, by a much greater extent in those scales with lowest completion rates.
Estimates of sample size in a future clinical trial. Based on the estimated annual rate of decline for each rating scale and its SD from these mixed models, we estimated the total number of participants required in a 2 parallelgroup randomized trial with similar measurement frequency to PRION-1 that would provide at least 80% power to detect a 50% relative reduction in annual rate of decline for that scale (2-sided ␣ ϭ 0.05) (table 2). In terms of subgroups, restricting enrollment through inclusion criteria in future trial designs to only "medium" progressors, or to those with Rankin 2-3 or 2-4 at enrollment, provides some advantages in terms of smaller sample sizes to detect reduced declines (table 2) , with "fast" progressors and those at most advanced disease stages clearly able to contribute less information (and potentially also with less ability to benefit from any intervention if substantial neurologic damage has already occurred). However, restricting eligibility clearly comes at the expense of slower recruitment, given the restricted patient population. If enrollment is unrestricted, imputing deaths as worst possible score when this has not previously been observed provides greater power than using observed data only, although it is a heuristic approach to the problems described above. For comparison, assuming 25% of patients survive 2 years, 3 then a total of 106 participants would be needed to detect an increase in survival from 25% to at least 50% (i.e., a relative 33% mortality reduction) with at least 80% power and 2-sided ␣ ϭ 0.05. This is about the same as the smallest total number needed to detect 50% reduction in declines in the different rating scales.
Proposed combination of Barthel with subcomponents of CDR-SB. Based on the validity and good performance of Barthel and CDR-SB in the analyses above (table e-1), we explored the utility of combinations of subcomponents of these scales. A proposed 30-point scale based on the entire Barthel with addition of modified memory, orientation, and judgment sub- Sample size estimates were based on 80% power, and a 2-sided significance level 5%. The severity stratified models were restricted to patients with baseline Rankin 2-3 or 2-4. In the imputed model the worst score was imputed for death (except for BPRS, see appendix e-1) and any subsequent scores after a patient recorded the worst score were discarded.
components from the CDR-SB has been included in the power calculations for comparison (table 2) . The CDR-SB subcomponents were selected on the basis of ease of use and validity in a prion disease patient population, confirmed by visualization of individual patient trajectories for each CDR-SB subcomponent. Further analyses to justify the choice of subcomponents and refine questions will be conducted in the National Prion Monitoring Cohort study.
DISCUSSION
The desired requirements of a rating scale in prion disease are clear. The scale should be related to the disease manifestation and progression, and should be important to patients and their carers. The scale should be able to measure one or both of these accurately by minimizing disease-unrelated variations, such as those due to the particular examiner, the degree of encouragement, or patient fatigue. To facilitate patient assessment, the scale should not take long to complete and the need for specialist training of the examiner should be minimal. A hallmark of prion diseases is their rapid evolution, which necessitates a scale that can perform across a wide severity range. Given that prion diseases are rare, a scale covering a wide range of severity, which is as simple, easy to measure, and reproducible as possible, and not subject to variation in implementation over calendar time, may be important for studies with broad entry criteria, those recruiting internationally, and those with prolonged recruitment periods. In table e-1, we assess the 8 scales used in PRION-1 against these requirements. Floor effects for cognitive and psychiatric scales were very strong in PRION-1. Serial cognitive/psychiatric measures were rarely obtained in sporadic CJD. Language output impairments have long been recognized as a classic clinical feature of sporadic CJD. 15 The frequency of this defect may overemphasize deterioration measured using the 3 cognitive/ psychiatric scales which rely heavily on spoken responses by the patient. The functional and global scales were also impacted to some extent by insensitivity in the advanced stages of disease. The GCS was most resistant to this problem, but suffered from a marked ceiling effect with many patients never scoring below the best possible score, and questionable relevance to progression of the disease. In general, the floor effects were partially ameliorated by imputation of the worst possible score for patients who had died. This also allowed for the inclusion of patients in models for decline who were otherwise excluded because no measurements were obtained. A disadvantage of the imputed model is that it is only based on a single imputation, and the strong impact of survival of survival, interrater reliability, and telephone use, among other issues, will be considered by the ongoing National Prion Monitoring Cohort study. The unusual opportunity afforded by PRION-1, to follow up patients through most of the clinical course to death, makes our conclusions relevant to other neurodegenerative diseases.
